FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807159098> ?p ?o ?g. }

• W2807159098 endingPage "8" @default.
• W2807159098 startingPage "1" @default.
• W2807159098 abstract "Abstract Background Combination therapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) chemotherapy drastically improves survival of advanced pancreatic cancer patients. However, the efficacy of FOLFIRINOX as a second‐line treatment after gemcitabine failure has not been tested prospectively. We investigated the feasibility and safety of attenuated FOLFIRINOX in patients with gemcitabine‐refractory advanced pancreatic cancer. Methods A multicenter phase II prospective open‐label, single‐arm study was conducted at 14 hospitals. Patients with histologically proven invasive ductal pancreatic adenocarcinoma, a measurable or evaluable lesion, Eastern Cooperative Oncology Group performance status 0 or 1, adequate organ function, and aged 19 years or older were eligible. Attenuated FOLFIRINOX consisted of oxaliplatin 65 mg/m 2 , irinotecan 135 mg/m 2 , and leucovorin 400 mg/m 2 injected intravenously on day 1 and 5‐fluorouracil 2000 mg/m 2 continuously infused intravenously over 46 h on days 1–2, repeated every 2 weeks. The primary endpoint was progression‐free survival from the initiation of FOLFIRINOX. Secondary endpoints were the objective response rate, disease control rate, overall survival, safety, and tolerability. We estimated overall survival and progression‐free survival using the Kaplan–Meier methods. Results We enrolled 39 patients from 14 institutions. The objective response rate was 10.3%, while the disease control rate was 64.1%. The 6‐month and 1‐year overall survival rates were 59.0% and 15.4%, respectively. Median progression‐free survival and overall survival were 3.8 months (95% confidence interval [CI] 1.5–6.0 months) and 8.5 months (95% CI 5.6–11.4 months), respectively. Grade 3 or 4 adverse events were neutropenia (41.0%), nausea (10.3%), anorexia (10.3%), anemia (7.7%), mucositis (7.7%), pneumonia/pleural effusion (5.1%), and fatigue (5.1%). One treatment‐related death attributable to septic shock occurred. Conclusion Attenuated FOLFIRINOX may be promising as a second‐line therapy for gemcitabine‐refractory pancreatic cancer." @default.
• W2807159098 created "2018-06-13" @default.
• W2807159098 creator A5001027928 @default.
• W2807159098 creator A5003756007 @default.
• W2807159098 creator A5007680812 @default.
• W2807159098 creator A5010509952 @default.
• W2807159098 creator A5011928803 @default.
• W2807159098 creator A5023107984 @default.
• W2807159098 creator A5025416763 @default.
• W2807159098 creator A5035019823 @default.
• W2807159098 creator A5038041478 @default.
• W2807159098 creator A5043984377 @default.
• W2807159098 creator A5060913021 @default.
• W2807159098 creator A5062021313 @default.
• W2807159098 creator A5063326703 @default.
• W2807159098 creator A5065847671 @default.
• W2807159098 creator A5068310127 @default.
• W2807159098 creator A5075932421 @default.
• W2807159098 creator A5083760245 @default.
• W2807159098 date "2018-06-04" @default.
• W2807159098 modified "2023-10-12" @default.
• W2807159098 title "Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study" @default.
• W2807159098 cites W1754783001 @default.
• W2807159098 cites W1906085213 @default.
• W2807159098 cites W1986733308 @default.
• W2807159098 cites W2006766434 @default.
• W2807159098 cites W2008532487 @default.
• W2807159098 cites W2014767306 @default.
• W2807159098 cites W2027249154 @default.
• W2807159098 cites W2036696042 @default.
• W2807159098 cites W2038012547 @default.
• W2807159098 cites W2050286878 @default.
• W2807159098 cites W2054625398 @default.
• W2807159098 cites W2089373384 @default.
• W2807159098 cites W2115658806 @default.
• W2807159098 cites W2151253787 @default.
• W2807159098 cites W2155637224 @default.
• W2807159098 cites W2158798157 @default.
• W2807159098 cites W2162758135 @default.
• W2807159098 cites W2164286021 @default.
• W2807159098 cites W2165480504 @default.
• W2807159098 cites W2317504614 @default.
• W2807159098 cites W2402503421 @default.
• W2807159098 cites W2407413178 @default.
• W2807159098 cites W2480793872 @default.
• W2807159098 cites W2568344912 @default.
• W2807159098 cites W2610989131 @default.
• W2807159098 cites W2614066012 @default.
• W2807159098 doi "https://doi.org/10.1186/s40880-018-0304-1" @default.
• W2807159098 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5993129" @default.
• W2807159098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29866170" @default.
• W2807159098 hasPublicationYear "2018" @default.
• W2807159098 type Work @default.
• W2807159098 sameAs 2807159098 @default.
• W2807159098 citedByCount "21" @default.
• W2807159098 countsByYear W28071590982019 @default.
• W2807159098 countsByYear W28071590982020 @default.
• W2807159098 countsByYear W28071590982021 @default.
• W2807159098 countsByYear W28071590982022 @default.
• W2807159098 countsByYear W28071590982023 @default.
• W2807159098 crossrefType "journal-article" @default.
• W2807159098 hasAuthorship W2807159098A5001027928 @default.
• W2807159098 hasAuthorship W2807159098A5003756007 @default.
• W2807159098 hasAuthorship W2807159098A5007680812 @default.
• W2807159098 hasAuthorship W2807159098A5010509952 @default.
• W2807159098 hasAuthorship W2807159098A5011928803 @default.
• W2807159098 hasAuthorship W2807159098A5023107984 @default.
• W2807159098 hasAuthorship W2807159098A5025416763 @default.
• W2807159098 hasAuthorship W2807159098A5035019823 @default.
• W2807159098 hasAuthorship W2807159098A5038041478 @default.
• W2807159098 hasAuthorship W2807159098A5043984377 @default.
• W2807159098 hasAuthorship W2807159098A5060913021 @default.
• W2807159098 hasAuthorship W2807159098A5062021313 @default.
• W2807159098 hasAuthorship W2807159098A5063326703 @default.
• W2807159098 hasAuthorship W2807159098A5065847671 @default.
• W2807159098 hasAuthorship W2807159098A5068310127 @default.
• W2807159098 hasAuthorship W2807159098A5075932421 @default.
• W2807159098 hasAuthorship W2807159098A5083760245 @default.
• W2807159098 hasBestOaLocation W28071590981 @default.
• W2807159098 hasConcept C121608353 @default.
• W2807159098 hasConcept C126322002 @default.
• W2807159098 hasConcept C141071460 @default.
• W2807159098 hasConcept C143998085 @default.
• W2807159098 hasConcept C197934379 @default.
• W2807159098 hasConcept C203092338 @default.
• W2807159098 hasConcept C2776283816 @default.
• W2807159098 hasConcept C2776694085 @default.
• W2807159098 hasConcept C2777148230 @default.
• W2807159098 hasConcept C2778375690 @default.
• W2807159098 hasConcept C2780210213 @default.
• W2807159098 hasConcept C2780258809 @default.
• W2807159098 hasConcept C2780259306 @default.
• W2807159098 hasConcept C2780456651 @default.
• W2807159098 hasConcept C2780739268 @default.
• W2807159098 hasConcept C2780962732 @default.
• W2807159098 hasConcept C31760486 @default.
• W2807159098 hasConcept C526805850 @default.
• W2807159098 hasConcept C535046627 @default.

• next